Related Experiment Video
Updated: Aug 11, 2026
23:56
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Insulin therapy: problems in an African country
Diabetic Medicine : a Journal of the British Diabetic Association
|September 1, 1985
Summary
Metabolic control is challenging for 40% of Ethiopian diabetic patients needing insulin. Factors like insulin cost, supply issues, and handling difficulties, compounded by socio-economic and religious factors, hinder effective diabetes management.
Area of Science:
- Endocrinology
- Public Health
- Global Health
Background:
- Metabolic control presents significant challenges for diabetic patients requiring insulin therapy.
- Approximately 40% of diabetic patients in Ethiopia face difficulties in managing their condition effectively.
Purpose of the Study:
- To identify and analyze the major problems affecting metabolic control in insulin-dependent diabetic patients in Ethiopia.
- To explore the contributing factors, including economic, social, religious, geographical, and logistical issues.
Main Methods:
- The study likely involved a review of existing data and potentially a survey or observational study.
- Analysis focused on factors impacting insulin accessibility, patient adherence, and healthcare follow-up.
Main Results:
- Key issues include the high cost of insulin, inconsistent supply chains, and challenges with syringe handling and sterility.
- Poor dietary control is exacerbated by economic and social factors, further complicated by religious customs.
- Inadequate follow-up care stems from geographical barriers and healthcare system limitations.
Conclusions:
- Addressing metabolic control in Ethiopian diabetic patients requires tackling multifaceted issues beyond clinical management.
- Interventions must consider economic support, improved insulin supply logistics, patient education on handling and hygiene, and enhanced healthcare infrastructure for follow-up.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...